Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics Inc (DE:F6T)
:F6T
F6T Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.78 - €6.74
Previous CloseN/A
Volume185.00
Average Volume (3M)628.00
Market Cap
€89.84M
Enterprise Value€214.25M
Total Cash (Recent Filing)$4.65M
Total Debt (Recent Filing)$3.19M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Apr 30, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding114,597,430
10 Day Avg. Volume1,135
30 Day Avg. Volume628
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.68
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap2.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.72
Enterprise Value/Ebitda-1.18
Forecast
1Y Price Target
€5.70Price Target Upside611.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentInitial Ph1 data from three patients with SLE shows B-cell depletion and clean safety; dose expansion to additional indications expected.
Financial StabilityFate Therapeutics ended the quarter with a cash position expected to fund operations through the end of 2026.
Regulatory SupportThe FDA agreed to allow the investigation of additional autoimmune diseases in the current Phase 1 study, indicating regulatory support.
Bears Say
Durability ConcernsPoor durability of response in the early systemic lupus erythematosus cohorts may be disappointing to investors.
Earnings PerformanceThe company's net loss per share was slightly higher than the consensus estimate, indicating a slight underperformance in expected earnings.
Price Target AdjustmentThe price target for Fate Therapeutics Inc has been adjusted downwards from $5 to $4 due to updated probability of success assumptions for their FT819 therapy.
---
Options Prices
Currently, No data available
---
Ownership Overview
18.11% Insiders
15.88%
Mutual Funds
39.29% Other Institutional Investors
16.39% Public Companies and
Individual Investors
F6T FAQ
What was Fate Therapeutics Inc’s price range in the past 12 months?
Fate Therapeutics Inc lowest stock price was €0.78 and its highest was €6.74 in the past 12 months.
What is Fate Therapeutics Inc’s market cap?
Fate Therapeutics Inc’s market cap is €89.84M.
When is Fate Therapeutics Inc’s upcoming earnings report date?
Fate Therapeutics Inc’s upcoming earnings report date is Apr 30, 2025 which is in 29 days.
How were Fate Therapeutics Inc’s earnings last quarter?
Fate Therapeutics Inc released its earnings results on Mar 05, 2025. The company reported -€0.407 earnings per share for the quarter, missing the consensus estimate of -€0.4 by -€0.007.
Is Fate Therapeutics Inc overvalued?
According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued.
Does Fate Therapeutics Inc pay dividends?
Fate Therapeutics Inc does not currently pay dividends.
What is Fate Therapeutics Inc’s EPS estimate?
Fate Therapeutics Inc’s EPS estimate is -0.36.
How many shares outstanding does Fate Therapeutics Inc have?
Fate Therapeutics Inc has 114,597,430 shares outstanding.
What happened to Fate Therapeutics Inc’s price movement after its last earnings report?
Fate Therapeutics Inc reported an EPS of -€0.407 in its last earnings report, missing expectations of -€0.4. Following the earnings report the stock price went down -6.652%.
Which hedge fund is a major shareholder of Fate Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:F6T
---
Fate Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.70 (611.95% Upside)
€5.70 (611.95% Upside)
Blogger Sentiment
Bullish
DE:F6T Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $31.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.43%
12-Months-Change
Fundamentals
Return on Equity
-54.21%
Trailing 12-Months
Asset Growth
-12.94%
Trailing 12-Months
Company Description
Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
---
F6T Stock 12 Month Forecast
Average Price Target
€5.70
▲(611.95% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering F6T
1 Year
1 Year Success Rate
5/28 ratings generated profit
1 Year Average Return
-21.91%
reiterated a buy rating 26 days ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 17.86% of your transactions generating a profit, with an average return of -21.91% per trade.
---